VEGF Trap-Eye, a human fusion protein consisting of portions of VEGF receptors 1 and 2, binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).
The VEGF Trap-Eye submission is based on the positive results from two Phase 3 trials, the VIEW 1 study and the VIEW 2 study.
In these trials, all regimens of VEGF Trap-Eye, including 2 mg VEGF Trap-Eye dosed every two months (following three loading doses) met the primary endpoint of non-inferiority, compared to the current standard of care, ranibizumab 0.5 mg dosed every month.
The study concluded with safety profile for both VEGF Trap-Eye and ranibizumab.
Regeneron Pharmaceuticals and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye for the treatment of wet AMD, central retinal vein occlusion (CRVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV).
Bayer HealthCare will market VEGF Trap-Eye outside the US, where the companies will share equally the profits from any future sales of VEGF Trap-Eye.
Regeneron maintains exclusive rights to VEGF Trap-Eye in the US.